title: Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management.
abstract: Late stage solid tumors cause significant cancer mortality rates worldwide and effective therapy remains a big challenge. Cancer therapeutic vaccines elicit tumor specific T cells that kill tumor cells yet often fail to result in tumor destruction because of the limited T cell response and the local immune-suppressive environment. Blocking interleukin 10 (IL-10) signaling at the time of therapeutic vaccination elicits much stronger T cell responses than vaccination without IL-10 blocking. Anaerobic oncolytic bacteria target hypoxic regions of the late stage tumor tissues which not only stops tumor growth but also provides a pro-inflammatory environment that may increase the effectiveness of a therapeutic vaccine by recruiting more effector T cells to tumor site. In this review, we argue that combining both bacterial and vaccine therapies may improve the efficiency of late stage cancer management.
authors.affiliation: a School of Medical Science and Griffith Health Institute, Griffith University , Gold Coast , QLD , Australia.|d Tangshan Supervision Institute of Health , Tangshan , China.
authors.forename: Guoying
authors.initials: G
authors.lastname: Ni
authors.affiliation: c Genecology Research Center, University of the Sunshine Coast , Maroochydore DC , QLD , Australia.
authors.forename: Tianfang
authors.initials: T
authors.lastname: Wang
authors.affiliation: f Department of Surgical Oncology , Tangshan Gongren Hospital , Tangshan , Hebei , China.
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
authors.affiliation: e Cancer Research Institute, Foshan First People's Hospital , Foshan, Guangdong , China.
authors.forename: Yuejian
authors.initials: Y
authors.lastname: Wang
authors.affiliation: b Inflammation and Healing Research Cluster, University of the Sunshine Coast , Maroochydore DC , QLD , Australia.|e Cancer Research Institute, Foshan First People's Hospital , Foshan, Guangdong , China.
authors.forename: Xiaosong
authors.initials: X
authors.lastname: Liu
authors.affiliation: a School of Medical Science and Griffith Health Institute, Griffith University , Gold Coast , QLD , Australia.
authors.forename: Ming Q
authors.initials: MQ
authors.lastname: Wei
mesh_terms: D000818:Animals; D001421:Bacteria, Anaerobic / Q000472:pathogenicity*; D019496:Cancer Vaccines / Q000276:immunology*; D003131:Combined Modality Therapy / Q000379:methods*; D006801:Humans; D016753:Interleukin-10 / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000628:therapy*; D015398:Signal Transduction; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D016753:Interleukin-10
keywords: anaerobic bacterial oncolysis; interleukin 10 (IL-10); therapeutic vaccine